Modified synthetic N-POMC 1-28 without disulfide bridges has been shown to act as an adrenal mitogen. Cyclins and their inhibitors are the major cell cycle controls, but in the adrenal cortex the effect of ACTH and N-POMC on the expression of these proteins remains unclear. In this work, we evaluate the effect of different synthetic N-POMC peptides on the S-phase of the cell cycle. In addition, we examine the cyclin E expression in rat adrenal cortex. Rats treated with dexamethasone were injected with ACTH and/or synthetic modified N-POMC and/or synthetic N-POMC with disulfide bridges. DNA synthesis was determined by BrdU incorporation and protein expression was analyzed by immunoblotting and immunohistochemistry. The results showed that similarly to modified N-POMC without disulfide bridges, administration of synthetic N-POMC with disulfide bridges and the combination of ACTH and N-POMC promoted an increase of BrdU-positive nuclei in adrenal cortex. However, the proliferative effect of N-POMC was comparable to that of ACTH only in the zona glomerulosa. An increase in cyclin E expression was observed 6 h after N-POMC treatment in the outer fraction of the adrenal cortex, in agreement with immunohistochemical findings in the zona glomerulosa. In summary, the effect of synthetic N-POMC with disulfide bridges was similar to modified synthetic N-POMC, increasing proliferation in the adrenal cortex, confirming previous evidence that disulfide bridges are not essential to the N-POMC mitogenic effect. Moreover, cyclin E appears to be involved in the N-POMC-and ACTH-stimulated proliferation in the zona glomerulosa of the adrenal cortex.
Introduction
Among pro-opiomelanocortin (POMC)-derived peptides, the adrenocorticotropic hormone (ACTH) is considered one of the main mitogenic stimuli for the adrenal cortex (New, 1998) . However, other POMC peptides different from ACTH seem also appear to have a role in adrenal cell proliferation. The N-terminal fragments of POMC, known as N-POMC, have been shown to stimulate adrenal cell proliferation (Estivariz et al., 1982; Lowry et al., 1983) . N-POMC and N-POMC 2-54 peptides were found to be potent mitogens both in vitro (Estivariz et al., 1982) and in vivo (Estivariz et al., 1988) . Furthermore, previous findings from our lab showed that administration of modified synthetic N-POMC 1-28 , without disulfide bridges, to dexamethasone (DEX)-treated rats induces
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S-phase entry in all zones of the adrenal cortex (Torres et al., 2010) . To promote tissue growth proliferating mammalian cells pass through an orderly sequence of phases that comprise the cell cycle (Pestell et al., 1999, for review) . Progression through G1 to S phase is promoted by cyclin D1 and cyclin E, which heterodimerize with catalytic subunits, the cyclin-dependent kinases (Cdks), to form active holoenzymes. These active holoenzymes phosphorylate substrates essential for progression through the restriction point of the cell cycle.
The aim of this work was to compare the effects of synthetic peptide N-POMC 1-28 with disulfide brides (N-POMC w ), and a modified peptide without disulfide bridges (N-POMC w/o ) on cell proliferation in the adrenal cortex using the well-known in vivo model of dexamethasone (DEX)-treated rats. In addition, the pattern of cyclin E expression was analyzed 6 h after administration of ACTH and/or N-POMC. Our results show that in contrast with synthetic modified N-POMC w/o , which increases DNA synthesis in all zones of the adrenal cortex, synthetic N-POMC w has a mitogenic effect only in the zona glomerulosa and zona reticularis of the adrenal cortex. In addition, within 6 h of N-POMC and ACTH treatment cyclin E expression in the zona glomerulosa was increased, suggesting the 0303-7207 © 2010 Elsevier Ireland Ltd. doi:10.1016/j.mce.2010.12.012
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involvement of this protein in the mitogenic effect on the adrenal cortex.
Materials and methods

Animals
Male Sprague-Dawley rats, weighing 250 ± 30 g, were obtained from the Biomedical Sciences Institute of the University of São Paulo and maintained in a temperature-controlled environment on a 12-h light/dark cycle. All protocols were approved by the Animal Experimentation Ethics Committee of the Biomedical Sciences Institute. The animals had free access to tap water and standard rat chow. All experiments were conducted between 9:00 am and 11:00 am. At the indicated time, rats were killed by decapitation, and the adrenal glands were harvested. Trunk blood was collected in chilled tubes containing 3.8% EDTA. The blood was separated into cellular and plasma fractions (10,000 rpm for 15 min at 4
• C), and the plasma was stored at −80
• C until analysis by chemiluminescent immunoassay for ACTH (Immulite; Diagnostic Products, Los Angeles, CA, USA).
N-POMC1-28 peptides synthesis
Two forms of rat N-POMC1-28 peptides were synthesized, with and without disulfide bonds, and at least two separate synthetic reactions were performed for the same peptide sequence. The rat N-POMC1-28 peptide without disulfide bonds (N-POMC w/o ) was synthesized by the Department of Biochemistry and Biophysics of the Federal University of São Paulo (UNIFESP). To avoid undefined disulfide bonds the peptide was synthesized with the replacement of cysteine 2, 8, 20 and 24 residues by methionine. Meanwhile, the rat N-POMC1-28 peptide with disulfide bonds (N-POMC w ) in the cysteine 2-24 and 8-20 positions was synthesized by Bachem America Inc. (Torrance, CA, USA).
Dexamethasone, ACTH and N-POMC1-28 treatments
The dexamethasone (Dex) (Aché Laboratórios Farmacêuticos, Campinas, SP, Brazil) treatment was performed as described in Baccaro et al. (2007) . Briefly, male Sprague-Dawley rats were divided into seven groups (n = 4-5): Dex or Dex + ACTH or Dex + N-POMC w/o or Dex + ACTH + N-POMC w/o or Dex + N-POMC w or Dex + ACTH + N-POMC w , and control. Dex was administered intraperitoneally at a dose of 50 g/100 g B.W. once a day at 9:00 am for 2 days. ACTH, N-POMC w and N-POMC w/o treatments were administered at a concentration of 10 −7 M in a dose of 100 l/100 g B.W. Control rats received identical injections of saline only.
Preparation of fractions and protein lysates
At 6 and 8 h after final treatments, rats were decapitated and the adrenal glands were promptly removed. Adherent adipose tissue was cleaned from the adrenal glands, which were then gently decapsulated to separate capsule/zona glomerulosa (outer fraction; OF) from zona fasciculata/reticularis and medulla (inner fraction; IF). Fractions were rapidly frozen in liquid nitrogen and the medulla was removed from IF. All samples were lysed in ice-cold RIPA (50 mM of Tris-HCl (pH 7.5), 150 mM of NaCl, 1% (v/v) Nonidet P-40, 1% (w/v) sodium deoxycholate, 0.1% SDS) and protease inhibitors (1 mM of phenylmethylsulfonyl fluoride, 2 g/ml of leupeptin, 2 g/ml of aprotinin and 2 g/ml of pepstatin). Samples were clarified by centrifugation and the protein concentration was quantified by the Bradford assay.
Characterization of fractions
Total lysate protein samples from IF and OF (30 g) were resolved by 10% SDS-PAGE. After electrophoresis, the gel was electroblotted onto Hybond-C nitrocellulose membranes using a semi-dry Bio-Rad apparatus. Non-specific sites were blocked overnight at 4
• C with 5% non-fat dried milk dissolved in TBS (150 mM NaCl, 10 mM Tris, 1% Tween 20, pH 7.5). Membranes were then incubated with one of the following antibodies: anti-cytochrome P450 aldosterone synthase (CYP11B2, 1:100; Chemicon-Millipore Corporate, Billerica, MA, USA), anti-cytochrome P450 11␤-hydroxylase (CYP11B1, 1:100; Chemicon), anti-tyrosine hydroxylase (TH, 1:5000; Immunostar Inc. Hudson, WI, USA), ␤-actin (1:2000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or ␣-actinin (1:2000; Santa Cruz) for 2 h at room temperature. Proteins were then visualized by chemiluminescent detection with secondary peroxidase-conjugated anti-rabbit polyclonal antibodies (ECL-Amersham-Pharmacia, Piscataway, NJ, USA).
BrdU incorporation
The protocol followed was that described in Torres and Lotfi (2007) . Briefly, at 12 h after final treatments, all animals received a single intraperitoneal injection of 100 g BrdU (Sigma, St. Louis, MO, USA) per 100 g BW. At 24 h after final treatments the rats were killed by decapitation, and adrenal glands removed, fixed and embedded in paraffin. Sections (3 m) were deparaffinized, rehydrated, endogenous peroxidase activity blocked with 0.3% hydrogen peroxide in methanol, hydrolyzed with 1.5 N HCl, and then incubated with monoclonal anti-mouse-BrdU antibody (Amersham Pharmacia Biotech, Uppsala, Sweden). Data obtained from each zone were averaged for each experimental group, and the standard error of the mean was calculated. After an analysis of variance (ANOVA), statistical comparisons were made using the Tukey-Kramer multiple comparisons test. Values of p ≤ 0.05 were considered statistically significant.
Immunoprecipitation of cyclin E
Cyclin E protein expression was analyzed by immunoprecipitation due to lack of specificity of the antibody when performing immunoblotting only. Total protein lysates (300 g) were incubated with 20 l of A-Agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at 4
• C. The supernatant obtained after centrifugation was incubated with 1 g of anti-cyclin E Sc-481 (Santa Cruz) or ␤-actin (Santa Cruz) overnight at 4
• C. Samples were immunoprecipitated with A-Agarose protein, and the pellet washed with RIPA buffer and boiled. Protein samples were resolved as described before and membranes were incubated with anti-cyclin E (1:1000; Santa Cruz) or ␤-actin (1:2000; Santa Cruz) for 2 h 30 min at room temperature. Chemiluminescent detection was performed as described above and immunoblot results were quantified by densitometric analysis using the Gel-Pro Imager and the quantification program Gel-Pro Imager kit-Version 1.0 for Windows. The results given are representative of three independent experiments. Ponceau staining was used to monitor protein transfer and total protein loaded.
Immunohistochemistry for cyclin E
At 6 h after final treatments rats were killed by decapitation; adrenal glands were removed, fixed in 4% paraformaldehyde in a solution of 0.1 M phosphate buffered saline (PBS; pH 7.4) for 8 h at room temperature, and then immersed in PBS plus 6% sucrose for 12 h. After being fixed and deparaffinized, the sections were rehydrated through a graded ethanol series, before being washed with sterile Milli-Q water, PBS, and PBS with 0.5% hydrogen peroxide. Sections were incubated in boiling citrate buffer (pH 6.0) for antigen retrieval, and background staining was blocked using a proprietary solution (Background Blocker; Diagnostic BioSystems, Pleasanton, CA, USA). Then, sections were washed and incubated in PBS with 1:250 monoclonal anti-cyclin E Sc-481 antibody (Sc-481; Santa Cruz). The immune complexes were detected by immunoperoxidase staining with the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) and visualized with diaminobenzidine (Sigma Fast; Sigma-Aldrich, St. Louis, MO, USA) followed by counterstaining with Harris' hematoxylin and a saturated solution of lithium carbonate. Adrenal sections incubated in non-immune primary sera tested negative (not shown). Sections of jejunum were used as positive controls.
Immunoreactive cell count
For the quantification of BrdU incorporation, ten to 15 areas (containing 90-100 nuclei/area) in each section were sampled randomly in the three zones of the adrenal cortex and examined with a 40× objective attached to a Nikon microscope equipped with a video camera. Images were digitalized using Image-Pro Plus, and all immunoreactive nuclear profiles, regardless of the intensity of the immunostaining, were counted. Each cortical zone of each adrenal gland was determined by the morphology/constitution of cells. The percentage of BrdU-labeled nuclei was determined, which is defined as the number of BrdU-positive nuclei expressed as a percentage of the total number of nuclei.
Results
Synthetic N-POMC w has the same biological effect as N-POMC w/o in ZG and ZR, but not in the ZF
In previous work (Torres et al., 2010) we demonstrated that the administration of synthetic modified N-POMC w/o to DEX-treated rats induces S-phase entry in all zones of the adrenal cortex. Here we described the effect of administration of synthetic N-POMC w on the number of BrdU-labeled nuclei in adrenal cortex. In DEX rats, administration of 10 −7 M N-POMC w significantly increased the percentage of BrdU-positive cell nuclei in the ZG and ZR, by 15% and 12% respectively (Figs. 1a, c and 2) . We observed the same effect in these zones after administration of N-POMC w/o (Torres et al., 2010) . Therefore, in contrast to N-POMC w/o , the N-POMC w did not significantly alter the number of BrdU-positive nuclei in the ZF. Moreover, in the ZR, where Dex administration blocked the BrdU incorporation observed in control rats, the N-POMC w treatment restored the number of BrdU-positive nuclei. ACTH treatment increased BrdU incorporation in all adrenal zones (Baccaro et al., 2007) and, also, was more effective than N-POMC w in increasing DNA synthesis in the ZR (40% versus 17%). Furthermore, in the ZG there was no difference in the number of BrdU-positive nuclei after N-POMC w and ACTH treatment. The combination ACTH + N-POMC w (Figs. 1 and 2d) showed distinct effects on different adrenal zones. There was a significant increase (20%) in BrdU-positive nuclei in the ZG, no significant effect in the ZF (p < 0.07) and a significant decrease (23%) in the number of BrdU-positive nuclei in the ZR. Administration of ACTH and N-POMC w in combination had a negative influence on the ZR, decreasing the number of BrdU-positive cells by 22.9% in relation to ACTH treatment alone. On the other hand, in the ZG and ZF, the same treatment did not change the number of BrdU-positive nuclei when compared with ACTH alone. In order to estimate the N-POMC levels achieved in the plasma after i.p. injection, we analyzed the ACTH concentration in the plasma of animals treated with 10 −7 M ACTH. We observed that 15 min after ACTH injection the concentration of ACTH in the circulation was 5.3 × 10 −11 M (240.0 ± 86.1 pg/ml), decreasing to 3.7 × 10 −11 M (168.2 ± 39.5 pg/ml) and 0.95 × 10 −11 M (43.2 ± 15.1 pg/ml), after 30 min and 2 h, respectively (Fig. S1) . Therefore, the ACTH concentration detected in the plasma is similar to the evening pulse of ACTH in rat plasma, which is reported as 151 ± 43 pg/ml (Usategui et al., 1976) . As the effect of N-POMC peptides observed in our experiments is of the same order of magnitude as that of ACTH, it is likely that the plasma N-POMC concentration is similar to that determined for ACTH.
Outer and inner fractions are representative of ZG and ZF + ZR
In order to determine the quality of samples after subdivision of the adrenal cortex, we analyzed the expression of Cyp11B2, Fig. 4 . Analysis of cyclin E expression 6 h after treatments. Adrenal gland outer (OF) and inner (IF) fraction preparations containing total protein were obtained from rats treated for two days with saline only (control) or with dexamethasone (DEX; 50 g/100 g B.W.) followed by ACTH (10 −7 M) and/or N-POMC w/o (10 −7 M). * p < 0.05. n = 3. Cyp11B1 and tyrosine hydroxylase (TH) in the outer (OF) and inner (IF) fractions obtained. We observed that Cyp11B2 was expressed in the OF but not in IF (Fig. 3a) , whereas expression of Cyp11B1 was stronger in IF, irrespective of whether the medulla was present or not (Fig. 3b) . Furthermore, the analysis of TH expression showed the efficiency of removal of the medulla from the IF (Fig. 3c) . These results characterized the OF and IF as representative of, respectively, ZG and ZF + ZR.
ACTH and N-POMC w/o increase cyclin E expression in the outer fraction of adrenal cortex
In DEX rats we observed a decrease of cyclin E expression compared to control in the OF but not in IF (Fig. 4a) . On the other hand, 6 h after treatment with ACTH, N-POMC w/o , or a combination of both, an increase of cyclin E expression was observed in the OF fraction (Fig. 4b) . At 8 h after ACTH and N-POMC w/o treatments cyclin E remained up-regulated in the OF (not shown). No change in cyclin E expression was observed in the IF in these animals in comparison with DEX rats.
Immunolocalization of cyclin E expression in adrenal cortex
The results of the immunohistochemistry assay show that cyclin E expression in DEX rats was more restricted to cells of the ZR and ZF, and mainly in the cytoplasm of the outer ZF cells (Fig. 5a) . Administration of ACTH, N-POMC w/o , N-POMC w or the combination of ACTH and N-POMC w/o or ACTH and N-POMC w (Fig. 5b-f) produced an increase in the number of cyclin E-positive cells (nuclei and cytoplasm) in the ZG. Interestingly, in the ZF a decrease in cyclin E labeling was observed in the cytoplasm of the constituent cells. Taken together these results show that N-POMC and ACTH are found to increase cyclin E expression in the outer zone of the adrenal cortex, irrespective of the analytical method used. Moreover, fractioning of the adrenal cortex is a reliable method to analyze protein expression in the adrenal cortex.
Discussion
In this study, we investigated the mitogenic effect of synthetic N-POMC 1-28 peptides on the adrenal cortex of rats previously treated with dexamethasone. We compared the mitogenic effect of modified synthetic N-POMC w/o peptide, without disulfide bridges and with cysteines replaced by methionines, and a synthetic N-POMC w with the disulfide bridges between Cys 2 and Cys 24 and between Cys 8 and Cys 20 . Our results show that N-POMC w increases the number of BrdU-positive nuclei only in the ZG and ZR, whereas treatment with N-POMC w/o increased the number of BrdU-positive cells in all zones of the adrenal cortex. The absence of a response to N-POMC w in the ZF is intriguing.
This observation raises a question concerning the differential composition of extracellular matrix (ECM) proteins and the microenvironment in rat adrenal cortex. In fact, the ECM and integrins are differentially expressed in rat adrenal cortex and moreover, in vitro, ACTH-induced proliferation in glomerulosa and fasciculata cells depends on the specific composition of the ECM (Otis et al., 2007) .
It is noteworthy that only in the ZG did both N-POMC 1-28 peptides show induction of DNA synthesis similar to that produced by ACTH 1-39 . Furthermore, N-POMC 1-28 was not found to potentiate the mitogenic action of ACTH 1-39 on the adrenal cortex. These results are in agreement with those of Fassnacht et al. (2003) who demonstrated that a synthetic N-POMC w is capable of stimulating proliferation of both adrenocortical tumor cells and primary cell cultures of bovine adrenal glands. However, these in vitro data contrast somewhat with the finding that peripheral administration of this peptide to POMC −/− mice reduces food intake and body weight but does not affect adrenal growth (Coll et al., 2006) .
The primary sequence of the amino terminal of POMC is highly conserved throughout mammals, suggesting an important biological role for this peptide (Seger and Bennett, 1986) . The arrangement of disulfide bridges at its extreme N-terminal end inducing a hairpin tertiary structure appeared to be essential for targeting POMC to the regulated secretory compartment of the cell (Denef et al., 2001) . Although N-POMC w/o is not a natural peptide its amino acid sequence is similar to that of N-POMC w . While the literature contains a body of data showing that the disulfide bridges are important to the biological effects of N-POMC, the largely comparable results obtained with the two peptides in the present study, as well as in previous work from our laboratory, suggest that the conformational properties of N-POMC w/o , without the disulfide bridges, can determine its proliferative effects in the adrenal cortex.
Using two different approaches we examined the role of cyclin E expression in the proliferation observed in the adrenal cortex after treatment with N-POMC w/o and ACTH. This resulted in experimental evidence to show that the protein fractioning of the adrenal cortex is a reliable approach. Moreover, we showed that 6 h after N-POMC or ACTH treatment the cyclin E expression was increased in the outer zone of the adrenal cortex, irrespective of the approach used. However, the decrease in cytoplasmic labeling for cyclin E among the outer ZF cells, at 6 h after ACTH and N-POMC administration, together with the increase in the number of cyclin E-positive cells in the ZG is enigmatic and of interest.
The present study shows that altered expression of the cell cycle regulator protein cyclin E and an increase in BrdU-positive nuclei are evidence of a role for cyclin E in the mitogenic effect of ACTH and N-POMC on the adrenal cortex.
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